Category Archives: Cell Therapy

EdiGene Announces Completion of Last Patient Dosing in Phase I Clinical Trial of ET-01, its Investigational Gene-editing Hematopoietic Stem Cell Therapy for Transfusion Dependent -thalassemia  Business Wire

Excerpt from:
EdiGene Announces Completion of Last Patient Dosing in Phase I Clinical Trial of ET-01, its Investigational Gene-editing Hematopoietic Stem Cell...

Radiation therapy uses high-energy rays or particles to kill cancer cells.

Depending on the stage of the non-small cell lung cancer (NSCLC) and other factors, radiation therapy might be used:

Different types of radiation therapy can be used to treat NSCLC. There are 2 main types:

External beam radiation therapy (EBRT) focuses radiation from outside the body onto the cancer. This is the type of radiation therapy most often used to treat NSCLC or its spread to other organs.

Treatment is much like getting an x-ray, but the radiation dose is stronger. The procedure itself is painless and each treatment lasts only a few minutes. Most often, radiation treatments to the lungs are given 5 days a week for 5 to 7 weeks, but this can vary based on the type of EBRT and the reason its being given.

Newer EBRT techniques have been shown to help doctors treat lung cancers more accurately while lowering the radiation exposure to nearby healthy tissues. These include:

Instead of giving a small dose of radiation each day for several weeks, SBRT uses very focused beams of high-dose radiation given in fewer (usually 1 to 5) treatments. Several beams are aimed at the tumor from different angles. To target the radiation precisely, you are put in a specially designed body frame for each treatment. This reduces the movement of the lung tumor during breathing.

A variation of IMRT is called volumetric modulated arc therapy (VMAT). It uses a machine that delivers radiation quickly as it rotates once around the body. This allows each treatment to be given over just a few minutes.

For more detailed descriptions of these procedures, see External Beam Radiation Therapy.

In people with NSCLC, brachytherapy is sometimes used to shrink tumors in the airway to relieve symptoms.

The doctor places a small source of radioactive material (often in the form of small pellets) directly into the cancer or into the airway next to the cancer. This is usually done through a bronchoscope, but it may also be done during surgery. The radiation travels only a short distance from the source, limiting the effects on surrounding healthy tissues. The radiation source is usually removed after a short time. Less often, small radioactive seeds are left in place permanently, and the radiation gets weaker over several weeks.

If you are going to get radiation therapy, its important to ask your doctor about the possible side effects so you know what to expect. Common side effects depend on where the radiation is aimed and can include:

Often these go away after treatment. When radiation is given with chemotherapy, the side effects may beworse.

Radiation therapy to the chest may damage your lungs and cause a cough, problems breathing, and shortness of breath. These usually improve after treatment is over, although sometimes they may not go away completely.

Your esophagus, which is in the middle of your chest, may be exposed to radiation, which could cause a sore throat and trouble swallowing during treatment. This might make it hard to eat anything other than soft foods or liquids for a while. This also often improves after treatment is finished.

Radiation therapy to large areas of the brain can sometimes cause memory loss, headaches, or trouble thinking. Usually these symptoms are minor compared with those caused by cancer that has spread to the brain, but they can affect your quality of life.

See the rest here:
Radiation Therapy for Non-Small Cell Lung Cancer

AvenCell to Present New Data from Lead Universal CAR T Cell Therapy Program at 64th American Society of Hematology Annual Meeting and Exposition  Business Wire

Here is the original post:
AvenCell to Present New Data from Lead Universal CAR T Cell Therapy Program at 64th American Society of Hematology Annual Meeting and Exposition -...

Instil Bio's stock falls 35% after disclosing the cell therapy company paused enrollment in clinical trials  MarketWatch

Read more:
Instil Bio's stock falls 35% after disclosing the cell therapy company paused enrollment in clinical trials - MarketWatch

Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem, a Novel Cell Therapy for the Treatment of Type 1 Diabetes  PR Newswire

Originally posted here:
Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem, a Novel Cell Therapy for the...

Photodynamic therapy is a two-step process. First, you will first receive a photosensitizer. The drug may be taken by mouth, spread on the skin, or given through an IV, depending on where the tumor is in the body. After 24 to 72 hours, most of the drug will have left normal cells but remain in cancer or precancer cells. Then your tumor will be exposed to the light source.

How the light is applied depends on where the tumor is. For skin tumors, the light is aimed right at the cancer. For tumors in the throat, airways, and lungs, your doctor will insert an endoscope down your throat. An endoscope is a thin, lighted tube that can help the doctor see inside the body. Once the endoscope is in place, the doctor threads a fiber optic cable that transmits light through it to reach the treatment areas.

One type of photodynamic therapy called extracorporeal photopheresis (ECP) is used to treat abnormal white blood cells that can cause skin symptoms in people withcutaneous T-cell lymphoma. In ECP, a machine collects your blood cells, treats them with a photosensitizer, exposes them to light, and then returns them to your body through a needle in a vein.

Most often, you will have photodynamic therapy as anoutpatient, which means you go home after treatment and do not spend the night in the hospital. You may have photodynamic therapy by itself, or you may have it along with other cancer treatments.

See more here:
Photodynamic Therapy to Treat Cancer - NCI

Researchers at University Hospitals create a breakthrough in CAR-T cell therapy for cancer patients  News 5 Cleveland WEWS

Read this article:
Researchers at University Hospitals create a breakthrough in CAR-T cell therapy for cancer patients - News 5 Cleveland WEWS

Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia  GlobeNewswire

Read the original post:
Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th...

1. Gilead, working to improve cancer cell therapy, partners with California startup  BioPharma Dive
2. Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers  Gilead Sciences
3. Kite Pharma Licenses Refuge Biotechnologies Platform to Bolster CAR T-Cell Therapy Development  Precision Oncology News
4. Gilead's Kite ties itself to Refuge's gene platform in blood cancer CAR-T deal  FierceBiotech
5. View Full Coverage on Google News

See the original post here:
Gilead, working to improve cancer cell therapy, partners with California startup - BioPharma Dive

Wilmington, Delaware, United States, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. The solutions in the global CAR T-cell therapy market are increasingly being hailed as cutting-edge innovations in the field of cancer treatments. Clinical trials conducted by players in the global CAR T-cell therapy market are displaying promising results, particularly in end stage patients suffering from acute lymphocytic leukemia. The success of these trials is translating into substantial revenue grab opportunities for market players. As per a recent professional survey report, the global CAR T-cell therapy market is estimated to grow at a CAGR of 30.6% over the forecast period of 2021 to 2031.

Players in the global CAR T-cell therapy market are working closely with research institutes and hospitals to develop cost-effective solutions, as the high cost of CAR T-cell therapies remains a major barrier for the adoption of these solutions. Chimeric Antigen Receptors or CAR are protein constructs that have been genetically engineered to be incorporated into patients cytotoxic T cells for aiding them in fighting cancer cells by efficiently recognizing them. Players in the global CAR T-cell therapy market offer various types of novel products, including tisagenlecleucel, lisocabtagene maraleucel, axicabtagene ciloleucel, brexucabtagene autoleucel, and idecabtagene vicleucel, among others.

Get Exclusive PDF Sample Copy of CAR T-cell Therapy Market https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=83242

CAR T-cell Therapy Market Key Findings of the Report

CAR T-cell Therapy Market Growth Drivers

Ask for References https://www.transparencymarketresearch.com/sample/sample.php?flag=ARF&rep_id=83242

CAR T-cell Therapy Market Key Players

Some of the key companies operating in the global CAR T-cell therapy market include Novartis AG, Amgen, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer, Inc., Bristol-Myers Squibb, Sorrento Therapeutics, Inc., Gilead Sciences, Inc., and bluebird bio, Inc., among others. Some of the noteworthy expansion strategies employed by these players include acquisitions, strategic alliances, geographical expansion, new product launches, and distribution agreements.

Furthermore, leading players in the global CAR T-cell therapy market are also focusing on research and development to design and develop new types of CAR T-cell therapy products intended for treating different types of cancer. Stakeholders in the global CAR T-cell therapy market are complying with various research and health policy frameworks in order to adhere to stringent regulations put forth by governments across the world.

CAR T-cell Therapy Market Regional Growth Assessment

In 2020, North America region held the dominant share of the global CAR T-cell therapy market. This leading industry positioning of the North America region can be attributed to the presence of a large number of leading international players, rising healthcare spending, and early adoption of new medical technologies and techniques. Furthermore, rising number of research activities in the region is also boosting growth within the North America CAR T-cell therapy market. In coming years, Asia Pacific is also expected to witness significant growth in the global market.

Make an Enquiry Before Buying https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=83242

CAR T-cell Therapy Market: Segmentation

CAR T-cell Therapy Market, by Product Type

CAR T-cell Therapy Market, by Indication

CAR T-cell Therapy Market, by End User

CAR T-cell Therapy Market, by Region

Modernization of healthcare in terms of both infrastructure and services have pushed the healthcare industry to new heights, Stay Updated with Latest Healthcare Research Reports by Transparency Market Research:

Ophthalmic Drugs Market: The ophthalmic drugs market is expected to reach US$ 50.2 Bn by the end of 2031 at a CAGR of 6.83% from 2022 to 2031.

Homeopathic Products Market: The global homeopathic products market is anticipated to reach more than US$ 32.4 Bn by the end of 2031 at a CAGR of 11.6% from 2022 to 2031.

Pain Management Therapeutics Market: The global pain management therapeutics market is anticipated to reach more than US$ 98.0 Bn by the end of 2031 at a CAGR of 2.9% from 2022 to 2031.

Peptide Therapeutics Market: The global peptide therapeutics market is anticipated to reach more than US$ 91.25 Bn by 2031 at a CAGR of 8.8% from 2022 to 2031.

Collagen Peptide & Gelatin Market: The global collagen peptide and gelatin market is anticipated to reach more than US$ 7.8 Bn by the end of 2031 at a CAGR of 5.0% from 2022 to 2031.

Premenstrual Syndrome Treatment Market: The global premenstrual syndrome treatment market is anticipated to reach more than US$ 1.9 Bn by the end of 2031 at a CAGR of 3.4% from 2022 to 2031.

Synthetic Biology Market: The global synthetic biology market is anticipated to reach more than US$ 74.7 Bn by the end of 2031 at a CAGR of 21.3% from 2022 to 2031.

Closed System Transfer Devices [CSTD] Market: The global closed system transfer devices (CSTD) market is expected to expand at a CAGR of ~11% from 2020-2030.

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyse information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit BhiseyTransparency Market Research Inc.CORPORATE HEADQUARTER DOWNTOWN,1000 N. West Street,Suite 1200, Wilmington, Delaware 19801 USATel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Website:https://www.transparencymarketresearch.comBlog:https://tmrblog.comEmail:sales@transparencymarketresearch.com

Link:
CAR T-cell Therapy Market Riding on the Wave of Growth and will Grow at a CAGR of 30.6% to 2031 | TMR Study - GlobeNewswire